Acrivon Therapeutics (Acrivon Therapeutics) Net-Net Working Capital : $4.30 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Acrivon Therapeutics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Acrivon Therapeutics's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $4.30.

The industry rank for Acrivon Therapeutics's Net-Net Working Capital or its related term are showing as below:

ACRV's Price-to-Net-Net-Working-Capital is ranked better than
79.05% of 926 companies
in the Biotechnology industry
Industry Median: 4.145 vs ACRV: 1.69

Acrivon Therapeutics Net-Net Working Capital Historical Data

The historical data trend for Acrivon Therapeutics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrivon Therapeutics Net-Net Working Capital Chart

Acrivon Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net-Net Working Capital

-0.70

-2.39

5.34

4.90

Acrivon Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net-Net Working Capital	Get a 7-Day Free Trial								5.04	6.35	5.84	4.90	4.30

Competitive Comparison of Acrivon Therapeutics's Net-Net Working Capital

For the Biotechnology subindustry, Acrivon Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrivon Therapeutics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Acrivon Therapeutics's Price-to-Net-Net-Working-Capital falls into.

Acrivon Therapeutics Net-Net Working Capital Calculation

Acrivon Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

	Net-Net Working Capital		(A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(127.458	+	0.75 * 0	+	0.5 * 0	-	17.07
-	0	-	0)	/	22.5226
=	4.90

Acrivon Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

	Net-Net Working Capital		(Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(109.975	+	0.75 * 0	+	0.5 * 0	-	12.542
-	0	-	0)	/	22.6375
=	4.30

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Acrivon Therapeutics (NAS:ACRV) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Acrivon Therapeutics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Acrivon Therapeutics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrivon Therapeutics (Acrivon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472

Website

https://www.acrivon.com

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Executives

Mary Miller	officer: Chief Legal Officer	C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Peter Blume-jensen	director, officer: President and CEO	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Chione Ltd	10 percent owner	SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101, 6015, LARNACA G4 CY
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Rasmus Holm-jorgensen	officer: Chief Financial Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Eric Devroe	officer: Chief Operating Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Anastasis Nikolaou	10 percent owner	C/O CHIONE LTD/ SIMOU MENARDOU 5, KIFISIA COURT,OFFICE 225, LARNACA G4 6015
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Erick Gamelin	officer: Chief Medical Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Kristina Masson	director, officer: EVP - Business Operations	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116